Coronary endothelial function in health and disease

Drugs

Volumn 53, Issue SUPPL. 1, 1997, Pages 20-29

  Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; GROWTH FACTOR; NATRIURETIC PEPTIDE TYPE C; NITRIC OXIDE; QUINAPRIL; VASOACTIVE AGENT; VASODILATOR AGENT;

ATHEROSCLEROSIS; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; ENDOTHELIUM; ENDOTHELIUM CELL; HEART BLOOD VESSEL; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERTENSION; META ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN SECRETION;

EID: 0031053855     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199700531-00005     Document Type: Conference Paper

References (43)

1. Florey HW. The endothelial cell. BMJ 1966; 2: 487-9
2. Marsden PA, Brenner BM. Nitric oxide and endothelins: novel autocrine/paracrine regulators of the circulation. Semin Nephrol 1991; 11: 169-85
3. Stingo AJ, Clavell AL, Aarhus LL, et al. Cardiovascular and renal actions of C-type natriuretic peptide. Am J Physiol 1992; 262(1 Pt 2): H308-12
4. Jougasaki M, Wei C-M, Aurhus LL, et al. Renal localization and actions of adrenomedullin: a natriuretic peptide. Am J Physiol 1995; 268: F657-63
5. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-5
6. Lerman A, Hildebrand F, O'Murchu B, et al. Endothelin: a new cardiovascular regulatory peptide. Mayo Clin Proc 1990; 65: 1441-55
7. Furchgott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 188: 373-6
8. Perrella MA, Hildebrand Jr FL, Margulies KB, et al. Endothelium-derived relaxing factor in the regulation of basal cardiopulmonary and renal function. Am J Physiol 1991; 261: R323-8
9. Ono H, Ono Y, Frohlich ED. Nitric oxide synthase inhibition in spontaneously hypertensive rats: systemic, renal, and glomerular hemodynamics. Hypertension 1995; 26: 249-55
10. Chu A, Chambers DE, Lin CC, et al. Effects of inhibition of nitric oxide formation on basal vasomotion and endothelium-dependent responses of the coronary arteries in awake dogs. J Clin Invest 1991; 87: 1964-8
11. Kullo IJ, Burnett Jr JC. C-type nutriuretic peptide: the vascular component of the natriuretic peptide system. In: Sowers JR, editor. Contemporary endocrinology: endocrinology of the vasculature. The endothelium. Totowa, NJ: Humana Press, 1996: 79-93
12. Wright RS, Wei CM, Kim CH, et al. C-type natriuretic peptide-mediated coronary vasodilation: role of the coronary nitric oxide and particulate guanylate cyclase systems. J Am Coll Cardiol 1996; 28: 1031-8
13. Supaporn T, Wennberg PW, Wei CM, et al. Role for the endogenous natriuretic peptide system in the control of basal coronary vascular tone in dogs. Clin Sci 1996; 90: 357-62
14. Wei CM, Hu S, Burnett Jr JC. Vascular actions of C-type natriuretic peptide in isolated porcine coronary arteries and coronary VSMCs. Biochem Biophys Res Commun 1994; 205: 756-71
15. Rubanyi GM, Vanhoutte PM. Hypoxia releases a vasoconstrictor suhstance from the canine vascular endothelium. J Physiol (Lond) 1985; 364: 45-56
16. Miller VM, Burnett Jr JC. Modulation of NO and endothelin by chronic increases in blood flow in canine femoral arteries. Am J Physiol 1992; 263 (1 Pt 2): H103-8
17. Miller WL, Redfield MM, Burnett Jr JC. Integrated cardiac, renal and endocrine actions of endothelin. J Clin Invest 1989; 83: 317-20
18. Weber H, Webb ML, Serafino R, et al. Endothelin-1 and angiotensin II stimulate delayed mitogenesis in cultured rat aortic smooth muscle cells: evidence for common signalling mechanisms. Mol Endocrinol 1994; 8: 148-58
19. Margulies KB, Hildebrand F, Burnett Jr JC. Increased endothelin in experimental heart failure. Circulation 1990; 82: 2226-30
20. Luscher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 1986; 8: 344-8
21. Lerman A, Edwards B, Hallet J, et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997-1001
22. Lerman A, Webster MWI, Chesebro JH, et al. Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. Circulation 1993; 88: 2923-8
23. Lerman A, Holmes D, Bell M, et al. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 1995; 92: 2426-31
24. Treasure CB, Vita JA, Cox DA, et al. Epicardial coronary artery responses to acetylcholine are impaired in hypertensive patients. Circ Res 1992; 72: 776-81
25. Treasure CB, Cox DA, Vita JA, et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993; 87: 86-93
26. Zeiher AM, Drexler H, Saurbier B, et al. Endothelium-mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993; 92: 652-62
27. Zeiher AM, Krause T, Schachinger V, et al. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation 1995; 91: 2345-52
28. Luscher TF, Noll G. Endothelium dysfunction in the coronary circulation. J Cardiovasc Pharmacol 1994; 24: 16S-26S
29. Minor Jr RL, Myers PR, Guerra Jr R, et al. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest 1994; 86: 2109-16
30. Clarkson P, Adams MR, Powe AJ, et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 1996; 97: 1989-94
31. Dartsch PC. In vitro growth characteristics of human atherosclerotic plaque cells: comparison of cells from primary stenosing and restenosing lesions of peripheral and coronary arteries. Res Exp Med 1990; 190: 77-87
32. Suga S, Nakao K. Phenotype-related alteration in expression of natriuretic peptide receptors in aortic smooth muscle cells. Circ Res 1992; 71: 34-9
33. Brown J, Chen Q. Regional expression of natriuretic peptide receptors during the formation of arterial neointima in the rabbit. Circ Res 1995; 77: 906-18
34. Kullo IJ, Muller VM, Lawson GM, et al. Dual inhibition of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE) suppresses atherogenesis and improves endothelial function in hypercholesterolemic rabbits [abstract]. J Am Coll Cardiol 1996; 27 (2 Suppl. A): 164A
35. Frielingsdorf J, Seiler C, Kaufmann P, et al. Normalization of abnormal coronary vasomotion by calcium antagonists in patients with hypertension. Circulation 1996; 93: 1380-7
36. Nonogy H, Hess OM, Ritter M, et al. Prevention of coronary vasoconstriction by diltiazem during dynamic exercise in patients with coronary artery disease. J Am Coll Cardiol 1988; 12: 892-9
37. Bertrand ME, Dupuis BA, Lablache JM, et al. Coronary hemodynamics following intravenous or intracoronary injection of diltiazem in man. Cardiovasc Pharmacol 1982; 4: 695-9
38. Kaltenbach M, Schulz W, Kober G. Effects of nifedipine after intravenous and intracoronary administration. Am J Cardiol 1979; 44: 832-8
39. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation; contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-23
40. Mancini GBJ, Henry GC, Macay C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94: 258-65
41. Clavell AL, Mattingly M, Stevens T, et al. Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. J Clin Invest 1996; 97: 1286-92
42. Cannan CR, Burnett Jr JC, Brandt RR, et al. Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor. Circulation 1995; 92: 3312-7
43. Bacon CR, Cary NRB, Davenport AP. Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta. Circ Res 1996; 79: 794-801